 Shares of Acceleron Pharma Inc. XLRN, 4.89 gained 3.9 in premarket trading on Monday after Bloomberg reported Friday that an unnamed buyer is considering spending 11 billion to buy the company. Acceleron markets one approved therapy, Reblozy, which is used to treat anemia in some people with the blood disorder beta thalassemia. 